Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 19/20 | 0.74 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4164930 | 0.99 | PTGER1 (0.73) | PTGER1PTGER3MAPTHTTSMN1; SMN2 | |
| SCHEMBL4660262 | 0.89 | PTGER1 (0.67) | PTGER1PTGER3MAPTHTTSMN1; SMN2 | |
| SCHEMBL4164379 | 0.86 | PTGER1 (0.62) | PTGER1PTGER3 | |
| SCHEMBL4161670 | 0.86 | PTGER1 (0.62) | PTGER1PTGER3 | |
| SCHEMBL13873917 | 0.86 | PTGER1 (0.61) | PTGER1PTGER3 | |
| SCHEMBL4161677 | 0.86 | PTGER1 (0.62) | PTGER1PTGER3 | |
| SCHEMBL4159251 | 0.85 | PTGER1 (0.62) | PTGER1PTGER3MAPTHTTSMN1; SMN2 | |
| SCHEMBL4165076 | 0.85 | PTGER1 (0.60) | PTGER1PTGER3MAPTHTTSMN1; SMN2 | |
| SCHEMBL4162156 | 0.85 | PTGER1 (1.00) | PTGER1PTGER3 | |
| SCHEMBL4176783 | 0.85 | PTGER1 (0.54) | PTGER1PTGER3MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | claimed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2001872-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885PTGER3 3/4885MAPT 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.